论文部分内容阅读
Over the last couple of years we have explored two hypotheses related to improving the value of natural products in the modem drug discovery paradigm.The fnrst hypothesis addressed the question whether natural products could display the physicochemical properties required in orally acting pharmaceuticals.In this area,we have published our work in developing a drug-like natural product library with properties that comply with Lipinski rules for orally active drugs.1 The second hypothesis addressed the question whether there was any similarity in recognition of a molecule in binding to the biosynthetic enzymes that produced the compound compared to the therapeutic target of the molecule.In this regard we have published a correlation between the recognition common to 3 biosynthetic enzymes in the flavonoid biosynthetic pathway and protein kinases.2 This lecture will address privileged scaffolds that are embedded in natural products.There are a set of scaffolds,within the drug-like natural product compound set that have been biosynthesized and hence recognize biology space,that control the orientation of the pendant groups resulting in protein interaction.Such privileged scaffolds offer new opportunities for lead discovery and lead modification.